Proteogenomic-based discovery of minor histocompatibility antigens with suitable features for immunotherapy of hematologic cancers

Leukemia

Volumn 30, Issue 6, 2016, Pages 1344-1354

  Granados, D P ^a,b   Rodenbrock, A ^a   Laverdure, J P ^a,b   Cote C ^a   Caron Lizotte, O ^a   Carli, C ^c   Pearson, H ^a,b   Janelle, V ^c   Durette, C ^a   Bonneil, E ^a   Roy, D C ^b,c,d   Delisle, J S ^b,c,d   Lemieux, S ^a,b   Thibault, P ^a,b   Perreault, C ^a,b,d  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MONTREAL   (Canada)

^d MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

MINOR HISTOCOMPATIBILITY ANTIGEN; TRANSCRIPTOME; HLA A2 ANTIGEN; HLA B44 ANTIGEN; HLA-A*02:01 ANTIGEN;

ALLELE; ALLOTYPE; ARTICLE; BIOINFORMATICS; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; EXOME; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOMICS; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; IMMUNOGENICITY; MALE; NORMAL HUMAN; NULL ALLELE; PRIORITY JOURNAL; PROTEOGENOMICS; PROTEOMICS; CELL CULTURE; HAPLOTYPE; HEMATOLOGIC NEOPLASMS; IMMUNOTHERAPY; PROCEDURES;

CELLS, CULTURED; FEMALE; HAPLOTYPES; HEMATOLOGIC NEOPLASMS; HLA-A2 ANTIGEN; HLA-B44 ANTIGEN; HUMANS; IMMUNOTHERAPY; MALE; MINOR HISTOCOMPATIBILITY ANTIGENS; PROTEOGENOMICS;

EID: 84960424202     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.22     Document Type: Article

References (58)

1. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015; 348: 69-74.
2. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015; 348: 62-68.
3. Sharma P, Allison JP. The future of immune checkpoint therapy. Science 2015; 348: 56-61.
4. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-1518.
5. Maus MV, Fraietta JA, Levine BL, Kalos M, Zhao Y, June CH. Adoptive immunotherapy for cancer or viruses. Annu Rev Immunol 2014; 32: 189-225.
6. Maus MV, Grupp SA, Porter DL, June CH. Antibody modified T cells: CARs take the front seat for hematologic malignancies. Blood 2014; 123: 2625-2635.
7. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005; 11: 1244-1249.
8. Vincent K, Roy DC, Perreault C. Next-generation leukemia immunotherapy. Blood 2011; 118: 2951-2959.
9. Mutis T, Brand R, Gallardo D, van BA, Niederwieser D, Goulmy E. Graft-versus-host driven graft-versus-leukemia effect of minor histocompatibility antigen HA-1 in chronic myeloid leukemia patients. Leukemia 2010; 24: 1388-1392.
10. Jenq RR, van den Brink MR. Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nat Rev Cancer 2010; 10: 213-221.
11. Roopenian D, Choi EY, Brown A. The immunogenomics of minor histocompatibility antigens. Immunol Rev 2002; 190: 86-94.
12. Mullally A, Ritz J. Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood 2007; 109: 1355-1362.
13. Granados DP, Laumont CM, Thibault P, Perreault C. The nature of self for T cells-a systems-level perspective. Curr Opin Immunol 2015; 34: 1-8.
14. Warren EH, Zhang XC, Li S, Fan W, Storer BE, Chien JW et al. Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood 2012; 120: 2796-2806.
15. Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443-458.
16. Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of T lymphocytes targeted to a single immunodominant minor histocompatibility antigen eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001; 7: 789-794.
17. Meunier MC, Delisle JS, Bergeron J, Rineau V, Baron C, Perreault C. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 2005; 11: 1222-1229.
18. Li N, Matte-Martone C, Zheng H, Cui W, Venkatesan S, Tan HS et al. Memory T cells from minor histocompatibility antigen-vaccinated and virusimmune donors improves GVL and immune reconstitution. Blood 2011; 118: 5965-5976.
19. Blankenstein T, Leisegang M, Uckert W, Schreiber H. Targeting cancer-specific mutations by T cell receptor gene therapy. Curr Opin Immunol 2015; 33: 112-119.
20. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
21. Spierings E, Hendriks M, Absi L, Canossi A, Chhaya S, Crowley J et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet 2007; 3: e103.
22. Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S et al. Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 2014; 515: 572-576.
23. Bleakley M, Riddell SR. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol 2011; 89: 396-407.
24. Hombrink P, Hassan C, Kester MG, Jahn L, Pont MJ, de Ru AH et al. Identification of biological relevant minor histocompatibility antigens within the B-lymphocytederived HLA-ligandome using a reverse immunology approach. Clin Cancer Res 2015; 21: 2177-2186.
25. Van Bergen CA, Rutten CE, Van Der Meijden ED, Van Luxemburg-Heijs SA, Lurvink EG, Houwing-Duistermaat JJ et al. High-throughput characterization of 10 new minor histocompatibility antigens by whole genome association scanning. Cancer Res 2010; 70: 9073-9083.
26. Granados DP, Sriranganadane D, Daouda T, Zieger A, Laumont CM, Caron-Lizotte O et al. Impact of genomic polymorphism on the repertoire of human MHC class I-associated peptides. Nat Commun 2014; 5: 3600.
27. Dolan BP, Sharma AA, Gibbs JS, Cunningham TJ, Bennink JR, Yewdell JW. MHC class I antigen processing distinguishes endogenous antigens based on their translation from cellular vs. viral mRNA. Proc Natl Acad Sci USA 2012; 109: 7025-7030.
28. Yewdell JW. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. Trends Immunol 2011; 32: 548-558.
29. Nesvizhskii AI. Proteogenomics: concepts, applications and computational strategies. Nat Methods 2014; 11: 1114-1125.
30. Fagerberg L, Hallstrom BM, Oksvold P, Kampf C, Djureinovic D, Odeberg J et al. Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol Cell Proteomics 2014; 13: 397-406.
31. Wolfl M, Greenberg PD. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat Protoc 2014; 9: 950-966.
32. Janelle V, Carli C, Taillefer J, Orio J, Delisle JS. Defining novel parameters for the optimal priming and expansion of minor histocompatibility antigen-specific T cells in culture. J Transl Med 2015; 13: 123.
33. Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, Gibbs RA et al. A map of human genome variation from population-scale sequencing. Nature 2010; 467: 1061-1073.
34. Spierings E. Minor histocompatibility antigens: past, present, and future. Tissue Antigens 2014; 84: 374-60.
35. Majewski J, Ott J. Distribution and characterization of regulatory elements in the human genome. Genome Res 2002; 12: 1827-1836.
36. Asakura S, Hashimoto D, Takashima S, Sugiyama H, Maeda Y, Akashi K et al. Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice. J Clin Invest 2010; 120: 2370-2378.
37. Flutter B, Edwards N, Fallah-Arani F, Henderson S, Chai JG, Sivakumaran S et al. Nonhematopoietic antigen blocks memory programming of alloreactive CD8+ T cells and drives their eventual exhaustion in mouse models of bone marrow transplantation. J Clin Invest 2010; 120: 3855-3868.
38. Fortier MH, Caron E, Hardy MP, Voisin G, Lemieux S, Perreault C et al. The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med 2008; 205: 595-610.
39. Hoof I, van Baarle D, Hildebrand WH, Kesmir C. Proteome sampling by the HLA class I antigen processing pathway. PLoS Comput Biol 2012; 8: e1002517.
40. Granados DP, Yahyaoui W, Laumont CM, Daouda T, Muratore-Schroeder TL, Cote C et al. MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. Blood 2012; 119: e181-e191.
41. Caron E, Vincent K, Fortier MH, Laverdure JP, Bramoullé A, Hardy MP et al. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol Syst Biol 2011; 7: 533.
42. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620-625.
43. Chappell P, Meziane EK, Harrison M, Magiera L, Hermann C, Mears L et al. Expression levels of MHC class I molecules are inversely correlated with promiscuity of peptide binding. Elife 2015; 4: e05345.
44. Schellens IM, Hoof I, Meiring HD, Spijkers SN, Poelen MC, van Gaans-van den Brink JA et al. Comprehensive analysis of the naturally processed peptide repertoire: differences between HLA-A and B in the immunopeptidome. PLoS One 2015; 10: e0136417.
45. Caron E, Espona L, Kowalewski DJ, Schuster H, Ternette N, Alpizar A et al. An open-source computational and data resource to analyze digital maps of immunopeptidomes. Elife 2015; 4: e07661.
46. Heath WR, Carbone FR. The skin-resident and migratory immune system in steady state and memory: innate lymphocytes, dendritic cells and T cells. Nat Immunol 2013; 14: 978-985.
47. Bollard CM, Barrett AJ. Cytotoxic T lymphocytes for leukemia and lymphoma. Hematol Am Soc Hematol Educ Program 2014; 2014: 565-569.
48. Yee C. The use of endogenous T cells for adoptive transfer. Immunol Rev 2014; 257: 250-263.
49. Perreault C, Roy DC, Fortin C. Immunodominant minor histocompatibility antigens: the major ones. Immunol Today 1998; 19: 69-74.
50. Choi EY, Christianson GJ, Yoshimura Y, Jung N, Sproule TJ, Malarkannan S et al. Real-time T-cell profiling identifies H60 as a major minor histocompatibility antigen in murine graft-versus-host disease. Blood 2002; 100: 4259-4264.
51. Kim J, Ryu SJ, Oh K, Ju JM, Jeon JY, Nam G et al. Memory programming in CD8(+) T-cell differentiation is intrinsic and is not determined by CD4 help. Nat Commun 2015; 6: 7994.
52. Rosinski SL, Stone B, Graves SS, Fuller DH, De Rosa SC, Spies GA et al. Development of a minor histocompatibility antigen vaccine regimen in the canine model of hematopoietic cell transplantation. Transplantation 2015; 99: 2083-2094.
53. Turtle CJ, Riddell SR. Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy. Curr Opin Immunol 2011; 23: 299-305.
54. Nauerth M, Weissbrich B, Knall R, Franz T, Dossinger G, Bet J et al. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci Transl Med 2013; 5: 192ra87.
55. Ghosh A, Holland AM, van den Brink MR. Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers. Immunol Rev 2014; 257: 226-236.
56. June CH, Riddell SR, Schumacher TN. Adoptive cellular therapy: a race to the finish line. Sci Transl Med 2015; 7: 280-7.
57. Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y et al. Toward eliminating HLA class I expression to generate universal cells from allogeneic donors. Blood 2013; 122: 1341-1349.
58. Inaguma Y, Akahori Y, Murayama Y, Shiraishi K, Tsuzuki-Iba S, Endoh A et al. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H. Gene Ther 2014; 21: 575-584.